{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.2","upperLimit":"10.3","value":"8.1"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"12.5","value":"9.3"},{"groupId":"OG002","lowerLimit":"2.6","upperLimit":"8.1","value":"5.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Measure the timing from the study start until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG000","title":"Cohort 1 - (Urothelial Progressive Disease)"},{"description":"Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG001","title":"Cohort 2 (Bone-only)"},{"description":"Patients with non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG002","title":"Cohort 3 (Rare Histologies)"}],"paramType":"MEDIAN","populationDescription":"42/50 were analyzed in cohort 1 because 5 participants withdrew, 2 were taken off study for adverse events and 1 was ineligible. In cohort 2, 5/6 patients were analyzed because 1 withdrew; and in cohort 3, 10/13 patients were analyzed because 1 withdrew and 2 were taken off study due to adverse events.","reportingStatus":"POSTED","timeFrame":"Median follow-up was 61.2 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}